<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334905</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-092</org_study_id>
    <nct_id>NCT01334905</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Single Oral Dose Study to Assess the Safety, Pharmacokinetics and Effect of Food on the Pharmacokinetics of Mirabegron (YM178) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Taiwan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate safety of YM178 and the effect of food intake on the
      pharmacokinetics of YM178 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A open-label, randomized, crossover study to assess the effect of food on the
      pharmacokinetics of single dose of YM178 administered under fasted and fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of YM178</measure>
    <time_frame>Up to 96 hrs post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the curve) of YM178 plasma concentration</measure>
    <time_frame>Up to 96 hrs post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax of YM178 plasma concentration</measure>
    <time_frame>Up to 96 hrs post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of YM178 plasma concentration</measure>
    <time_frame>Up to 96 hrs post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, clinical lab tests, vital signs, 12-lead ECGs and physical exam.</measure>
    <time_frame>Up to 96 hrs post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>Pharmacokinetics of YM178</condition>
  <arm_group>
    <arm_group_label>Part A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fasted condition then fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fed condition then fasted condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM178</intervention_name>
    <description>oral</description>
    <arm_group_label>Part A group</arm_group_label>
    <arm_group_label>Part B group</arm_group_label>
    <other_name>mirabegron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A normal or clinically non-significant 12 lead ECG as well as normal or clinically
             non-significant laboratory test results at the time of Screening

          -  Body weigh at least 50 kg in male and 45 kg in female and body mass index (BMI)
             between 18.5 and 26.9 kg/m2

          -  All women of child bearing potential are required to use adequate contraception
             consisting of two forms of birth control

        Exclusion Criteria:

          -  Hypersensitivity to YM178 or other beta-3 agonists or any of the constituents of the
             formulation used

          -  Liver function test values above the upper limit of normal

          -  A history or presence of psychiatric illness, serious active or recurrent infection

          -  A previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell
             carcinoma that has not been in remission for at least 5 years prior to the study

          -  Donated or lost â‰¥ 500 mL blood within 3 months or donated plasma within 2 weeks prior
             to the study

          -  Receiving or being anticipated to receive a prescription drug or OTC medications
             within 14 days prior to the study

          -  Consuming alcohol, xanthine derivative-containing food/beverages (tea, chocolate),
             grapefruit juice, grapefruit-containing products or Seville oranges (e.g., bitter
             marmalade) within 48 hours before the study

          -  A history of substance abuse, drug addiction, or alcoholism within past 2 years prior
             to the study

          -  currently participating in another clinical trial or taking or has been taking an
             investigational drug at least 60 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=628</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>June 10, 2013</last_update_submitted>
  <last_update_submitted_qc>June 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>YM178</keyword>
  <keyword>mirabegron</keyword>
  <keyword>Food effect</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

